An open-label, phase II study of matured dendritic cells pulsed ex vivo with 3 melanoma cell line lysates (IDD-3) with or without peginterferon alpha-2b (PegIFN-a 2b) in patients with resected stage II or III melanoma
Latest Information Update: 02 Nov 2011
At a glance
- Drugs IDD 3 (Primary) ; Peginterferon alfa-2b
- Indications Malignant melanoma
- Focus Therapeutic Use
- Sponsors IDM Pharma
- 02 Nov 2011 New source identified (European Clinical Trials Database)
- 06 Mar 2007 New trial record.